Disruption of the kappa-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective kappa-agonist U-50,488H and attenuates morphine withdrawal
about
Genetic susceptibility to heroin addiction: a candidate gene association studyDynorphin, stress, and depressionKappa-opioid ligands in the study and treatment of mood disorders15 years of genetic approaches in vivo for addiction research: Opioid receptor and peptide gene knockout in mouse models of drug abuseRole of kappa-opioid receptors in stress and anxiety-related behavior.Reduced Contextual Discrimination following Alcohol Consumption or MDMA Administration in MiceCognitive Impairment Induced by Delta9-tetrahydrocannabinol Occurs through Heteromers between Cannabinoid CB1 and Serotonin 5-HT2A Receptorskappa Opioid receptor interacts with Na(+)/H(+)-exchanger regulatory factor-1/Ezrin-radixin-moesin-binding phosphoprotein-50 (NHERF-1/EBP50) to stimulate Na(+)/H(+) exchange independent of G(i)/G(o) proteinsCyclophosphamide cystitis in mice: behavioural characterisation and correlation with bladder inflammationMu opioid receptors on primary afferent nav1.8 neurons contribute to opiate-induced analgesia: insight from conditional knockout miceCRF1-R activation of the dynorphin/kappa opioid system in the mouse basolateral amygdala mediates anxiety-like behaviorAnti-nociception mediated by a κ opioid receptor agonist is blocked by a δ receptor agonistCross-Talk between Metabolism and Reproduction: The Role of POMC and SF1 NeuronsAdenylyl cyclase type 5 (AC5) is an essential mediator of morphine action.30 years of dynorphins--new insights on their functions in neuropsychiatric diseasesIncreased opioid dependence in a mouse model of panic disorder.Proteasome involvement in agonist-induced down-regulation of mu and delta opioid receptors.The behavioral, anatomical and pharmacological parallels between social attachment, love and addiction.kappa-Opioid receptors control the metabolic response to a high-energy diet in miceNicotine anxiogenic and rewarding effects are decreased in mice lacking beta-endorphin.Contribution of mu and delta opioid receptors to the pharmacological profile of kappa opioid receptor subtypes.The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuseThe role of kappa-opioid receptor activation in mediating antinociception and addiction.Modulation of pain transmission by G-protein-coupled receptors.Increases in the risk of cognitive impairment and alterations of cerebral β-amyloid metabolism in mouse model of heart failurePharmacology and anti-addiction effects of the novel κ opioid receptor agonist Mesyl Sal B, a potent and long-acting analogue of salvinorin A(-)-Pentazocine induces visceral chemical antinociception, but not thermal, mechanical, or somatic chemical antinociception, in μ-opioid receptor knockout mice.κ-Opioid receptors are not necessary for the antidepressant treatment of neuropathic painInteractions of the opioid and cannabinoid systems in reward: Insights from knockout studies.When the DREAM is gone: from basic science to future prospectives in pain management and beyond.Design, synthesis, and biological evaluation of 14-heteroaromatic-substituted naltrexone derivatives: pharmacological profile switch from mu opioid receptor selectivity to mu/kappa opioid receptor dual selectivityInflammatory pain is enhanced in delta opioid receptor-knockout miceInvolvement of neuropeptide FF receptors in neuroadaptive responses to acute and chronic opiate treatments.Lack of genotype effect on D1, D2 receptors and dopamine transporter binding in triple MOP-, DOP-, and KOP-opioid receptor knockout mice of three different genetic backgroundsReward processing by the opioid system in the brain.Opioids and the gut: pharmacology and current clinical experience.Effects of combined opioids on pain and mood in mammals.Drug management of visceral pain: concepts from basic research.The antiallodynic action of pregabalin in neuropathic pain is independent from the opioid system.The endogenous opioid system in cocaine addiction: what lessons have opioid peptide and receptor knockout mice taught us?
P2860
Q24634090-B55A2DED-8460-4347-BEBB-3CFD3EAF1D4FQ24650168-6EDEB2A7-10C0-43EB-ADEA-4538BD44790BQ24657982-240DD326-4DAA-41A5-87A1-FB397F0B3B7FQ26824667-8DEBFA18-AA70-4604-8DF0-40B3584CF476Q26991739-582EFBE7-2814-4E8B-AA7E-9FB29FD462A9Q27342762-E58F2F7E-6F12-4693-B145-7A7737E15F59Q27347603-E8161C19-6D72-47A8-A737-62FEA70FCACCQ28255347-F23FB08B-D510-4E61-AA58-3236AF774E1FQ28372123-FCC68368-B94D-43BA-A0F2-F7C423F957EBQ28533332-06A253E0-C2F2-4AFF-8EE5-AF3D1B6AB833Q28580222-83388724-EEFB-4B38-AA13-1A983A0B793FQ28652289-1A9D3ED8-BFF6-4D09-98E0-97A71002914FQ30426775-C6BE228E-D64E-48CE-B6BE-825FBAD4910CQ30477757-BDCEFC1D-C7B6-4F84-9452-A75939B2E731Q30481450-CAB7921D-9B3F-45AB-A4D7-FC24860095D2Q30493463-4D4F31B3-4CF1-4F7D-9D99-26A2E31FB072Q31816606-FCA45E67-BA1E-4D75-A1EC-02582084F52AQ33455500-858CBF0E-827B-4F58-B16A-F3C3443EB0A3Q33752916-253F0102-794A-40C7-BEE9-599561583C5EQ33802867-9A9AA54B-E11A-4127-8509-0B599CA60B35Q33863139-42ED103A-A478-46B8-80D0-68BD7B941D88Q33890721-62779397-844A-4803-925C-39E602AF3F3CQ34132638-F0ED65F4-DC4F-4BE0-8E6C-AE8DF336CD66Q34247711-A445F212-ADF9-4186-9A2E-85FA290125E3Q34758476-6DD083B6-8C07-4557-AD07-150AF1BB577FQ34939810-0B3093C8-EDCB-46ED-864B-B58493FF2777Q34957270-BF298BE3-5C84-4146-A487-5DF122CC8077Q35039212-E41A71CE-B323-4F4D-95D3-47AACC53B9FFQ35053193-C6ACE33E-EECF-46EE-8B02-5C851179FAFEQ35095159-80BAB0EC-2401-4C1C-9D71-CF06F3E2F15DQ35216655-3FB2411B-5937-4BA6-8C47-C1C2E775D180Q35653788-F2A95C02-5DB3-48F9-BF26-B8FF0955DFAEQ35708164-4C57A8B8-EEDB-4E6A-9929-78F9658148D8Q35765802-8C88CD32-81AB-4459-9DFF-692914DE70B6Q35786247-C513015F-4F0C-4F20-93EC-CC3BC579B2C8Q35860904-063D7CC0-2AEB-45DE-8EF7-521AAC298CE9Q35884913-9CE9D6DF-27B0-4B03-8998-062E50D0791DQ35947915-4B1703F2-D269-468A-9C33-989B4D62D43CQ35974778-35D2FCD4-4EA4-4C36-B91B-CEA079A5CA21Q36110480-7C008B2E-63A5-4413-AA96-B4D7A79A174A
P2860
Disruption of the kappa-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective kappa-agonist U-50,488H and attenuates morphine withdrawal
description
1998 nî lūn-bûn
@nan
1998 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Disruption of the kappa-opioid ...... attenuates morphine withdrawal
@ast
Disruption of the kappa-opioid ...... attenuates morphine withdrawal
@en
Disruption of the kappa-opioid ...... attenuates morphine withdrawal
@nl
type
label
Disruption of the kappa-opioid ...... attenuates morphine withdrawal
@ast
Disruption of the kappa-opioid ...... attenuates morphine withdrawal
@en
Disruption of the kappa-opioid ...... attenuates morphine withdrawal
@nl
prefLabel
Disruption of the kappa-opioid ...... attenuates morphine withdrawal
@ast
Disruption of the kappa-opioid ...... attenuates morphine withdrawal
@en
Disruption of the kappa-opioid ...... attenuates morphine withdrawal
@nl
P2093
P2860
P921
P3181
P356
P1433
P1476
Disruption of the kappa-opioid ...... attenuates morphine withdrawal
@en
P2093
Kieffer BL
Maldonado R
Valverde O
P2860
P304
P3181
P356
10.1093/EMBOJ/17.4.886
P407
P577
1998-02-01T00:00:00Z